ArticleJournal of the American Heart Association2018
Assessing Baseline and Temporal Changes in Cardiometabolic Risk Using Metabolic Syndrome Severity and Common Risk Scores.
Article in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 34 citations in OpenAlex.
- Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome.The Journal of clinical endocrinology and metabolism · 2025Trial
- Cost and cost-effectiveness of the 'Stand and Move at Work' multicomponent intervention to reduce workplace sedentary time and cardiometabolic risk.Scandinavian journal of work, environment & health · 2022Trial
- Optimizing the Interaction of Exercise Volume and Metformin to Induce a Clinically Significant Reduction in Metabolic Syndrome Severity: A Randomised Trial.International journal of environmental research and public health · 2020Trial
- Use of a Metabolic Syndrome SeverityDiabetes care · 2018Trial
- Cardiometabolic risk profile and associated factors among adults with type 2 diabetes in a primary health care clinics in North Central Nigeria.African journal of primary health care & family medicine · 2026Article
- Article
- Stand up for your health: Rationale and design for a randomized controlled trial.Contemporary clinical trials · 2026Article
- Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting.Discover oncology · 2026Review
- An online interpretable machine learning model for predicting cardiometabolic multimorbidity risk in patients with type 2 diabetes mellitus.Scientific reports · 2026Article
- Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis.Frontiers in cardiovascular medicine · 2026Article
- Low-cost bodyweight callisthenic-based HIIT improves blood pressure, glucose control, and TyG in older adults with metabolic syndrome.Frontiers in sports and active living · 2026Article
- Intensive weight loss intervention versus usual care in adults with obesity: a protocol for the LightCARE randomised clinical trial.BMJ open · 2025Article
- Simple step counting captures comparable health information to complex accelerometer measurements.Journal of internal medicine · 2025Article
- Differences of Sedentary Behavior, Physical Activity, and Metabolic Syndrome Severity Among Metabolic Syndrome Clusters.American journal of lifestyle medicine · 2025Article
- Fitness-related physical activity intensity explains most of the association between accelerometer data and cardiometabolic health in persons 50-64 years old.British journal of sports medicine · 2024Article
- Accelerometer-measured absolute versus relative physical activity intensity: cross-sectional associations with cardiometabolic health in midlife.BMC public health · 2023Article
- Trajectory patterns of metabolic syndrome severity score and risk of type 2 diabetes.Journal of translational medicine · 2023Article
- Longitudinal changes in blood biomarkers and their ability to predict type 2 diabetes mellitus-The Tromsø study.Endocrinology, diabetes & metabolism · 2022Article
- Comparison of Leisure Time Physical Activities by Metabolic Syndrome Status among Adolescents.International journal of environmental research and public health · 2022Article
- Contribution of Components of Metabolic Syndrome to Cognitive Performance in Middle-Aged Adults.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Background Type 2 diabetes mellitus (T2 DM ) is considered a cardiovascular disease ( CVD ) risk equivalent, thereby linking assessment of cardiometabolic risk with that of CVD risk over time. Our goal was to determine how commonly used CVD risk scores and metabolic syndrome (MetS) severity performed in predicting T2 DM with and without ultimate CVD . Methods and Results We assessed data from 8273 participants of the ARIC (Atherosclerosis Risk in Communities) Study, using the pooled cohort atherosclerotic CVD risk score, the Framingham Risk Score, and a MetS severity Z score to assess their association with future risk for CVD alone, T2 DM alone, or both over 20 years of follow-up. Baseline levels of all scores were significantly associated with isolated incident T2 DM (odds ratios [ OR s] for each 1- SD increase: atherosclerotic CVD =1.7, Framingham risk score=1.7, MetS Z score=5.1). All 3 baseline scores were also significantly associated with isolated incident CVD (atherosclerotic CVD OR =2.4, Framingham risk score OR =2.3, MetS Z-score OR =1.8), with the 2 CVD scores remaining significant independent of MetS severity. MetS severity was strongly associated with future T2 DM leading to CVD (MetS Z-score OR =7.0, atherosclerotic CVD OR =3.9, Framingham risk score OR =3.5). Furthermore, changes in MetS severity were independently associated with future T2 DM - CVD progression. Conclusions CVD risk scores are associated with risk for future isolated T2 DM in addition to isolated CVD . However, MetS severity (both baseline and changes over time) was more strongly associated with T2 DM , including T2 DM ultimately leading to CVD . Following MetS severity within patients over time may identify those at greatest risk of combined cardiometabolic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.